ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

duvelisib

Also written as “Duvelisib”, “IPI-145” and “IPI-145 (duvelisib)”.

Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma · Lymphoma, Follicular · Hematologic Neoplasms · Mycosis Fungoides, led by 3 companies.

Drug pageDuvelisib: every studyAll 50 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 13, 201326 company-led studies, 2 open or runningNext primary completion: Feb 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
SecuraBio232 open or runningphase 3since Nov 13, 2013Nov 17, 2011Feb 2028phase 3 · NCT06522737
AbbVieits history only20 open or runningphase 1since Oct 21, 2015Oct 21, 2015none ahead
CSPC Pharmaceutical Groupits history only10 open or runningphase 2since Apr 24, 2020Apr 24, 2020none ahead

Also a collaborator on its studies: Infinity Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of SecuraBio only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 8 studies since Nov 17, 2011.

  1. Nov 13, 2013Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT02004522 · 319 enrolled · United States, Australia, Austria and more
  2. Jan 28, 2014Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT02049515 · 99 enrolled · United States, Australia, Austria and more
  3. Mar 21, 2014Phase 1 study in Hepatic ImpairmentNCT02095587 · 24 enrolled · United States
  4. Jul 25, 2014Phase 3 study in Lymphoma, FollicularNCT02204982 · 13 enrolled · Australia, France, Italy and more
  5. Nov 10, 20142 phase 1 studiesNCT02292225, NCT02307461
  6. Oct 7, 2015Phase 3 study in Lymphoma, FollicularNCT02576275 · United States
  7. Nov 4, 2015Phase 2 study in LymphomaNCT02605694 · United States
  8. Mar 15, 2016Phase 2 study in Hematologic NeoplasmsNCT02711852 · 19 enrolled · United States, Italy
  9. Nov 29, 2017Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT03370185 · United States
  10. Dec 1, 2017Phase 2 study in Lymphoma, T-Cell, PeripheralNCT03372057 · 156 enrolled · United States, Germany, Italy and more
  11. Jul 10, 2019Phase 2 study in Indolent Non-Hodgkin LymphomaNCT04038359 · 103 enrolled · United States, Czechia, Germany and more
  12. Dec 4, 2019Phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT04193293 · 2 enrolled · United States
  13. Jul 22, 2024Phase 3 study in LymphomaNCT06522737 · 124 planned · Belgium, Czechia, Denmark and more
  14. Jul 15, 2026Phase 1 study in Mycosis FungoidesNCT07714187 · 30 planned · United States

Ahead

  1. Feb 2028Primary completion: phase 3 study in LymphomaNCT06522737
  2. Oct 2028Primary completion: phase 1 study in Mycosis FungoidesNCT07714187

TargetBeta

“PI3-kinase p110-delta subunit inhibitor; PI3-kinase p110-gamma subunit inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
gedatolisibrulePfizerphase 39
paxalisibrulekazia-therapeutics-limitedphase 24

Studies

All 23 SecuraBio leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07714187Mycosis Fungoides · United States1Not yet recruitingOct 202830
NCT06522737Lymphoma · Belgium, Czechia, Denmark and more3RecruitingFeb 2028124
NCT04193293Squamous Cell Carcinoma of Head and Neck · United States2TerminatedDec 10, 20202
NCT04038359Indolent Non-Hodgkin Lymphoma · United States, Czechia, Germany and more2CompletedJul 24, 2023103
NCT03372057Lymphoma, T-Cell, Peripheral · United States, Germany, Italy and more2CompletedDec 22, 2023156
NCT03370185Leukemia, Lymphocytic, Chronic, B-Cell · United States2WithdrawnJun 20200
NCT02711852Hematologic Neoplasms · United States, Italy2CompletedMay 4, 202019
NCT02605694Lymphoma · United States2WithdrawnNov 20160
NCT02576275Lymphoma, Follicular · United States3WithdrawnNov 20160
NCT02307461Healthy · United States1CompletedAug 2015103
NCT02292225Leukemia, Lymphocytic, Chronic, B-Cell · United States, Canada1TerminatedNov 20163
NCT02204982Lymphoma, Follicular · Australia, France, Italy and more3TerminatedDec 201613
NCT02095587Hepatic Impairment · United States1CompletedJul 201424
NCT02049515Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more3CompletedJun 12, 202099
NCT02004522Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more3CompletedMay 19, 2017319
NCT01947777Healthy · United States1CompletedNov 201314
NCT01925911Healthy · United States1CompletedSep 201314
NCT01882803Indolent Non-Hodgkin Lymphoma · United States, Belarus, Belgium and more2CompletedNov 18, 2020129
NCT01851707Arthritis, Rheumatoid · Bulgaria, Colombia, Germany and more2CompletedDec 2014322
NCT01836861Healthy · Netherlands1CompletedApr 20136
NCT01653756Asthma · Germany, United Kingdom2CompletedAug 201450
NCT01549106Healthy Volunteers · Netherlands1CompletedFeb 2012106
NCT01476657Hematologic Neoplasms · United States1TerminatedDec 2016210

How it is read

Names in the registry

  • “Duvelisib”, 16 entries
  • “IPI-145”, 9 entries
  • “IPI-145 (duvelisib)”, 3 entries
  • “IPI-145, a PI3K Inhibitor”, 1 entry
  • “duvelisib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.